The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

October 11, 2021 • By Michael Putman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Some of the studies showed that a lot of the patients who had intervention or surgery when the vessel was actively inflamed did not do as well.9 So that’s also a consideration.

You Might Also Like
  • Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis
  • Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis
  • Vasculitis Guidelines in Focus, Part 1: The Guideline Project
Explore This Issue
February 2022

Another consideration is that, in general for renal artery stenosis, regardless of the type of artery stenosis, treatment with anti-hypertensives is preferred initially.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Again, there are some caveats. If you have a patient with critical organ or extremity ischemia, stroke-type symptoms or myocardial ischemia, you may need to intervene immediately.

The guideline recommends either a surgical procedure or a catheter-based procedure in those cases. Ideally, however, such a patient would be treated with high-dose glucocorticoids prior to the procedure to try to control the inflammation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

We also thought it was important to bring the vascular surgeon into discussions to decide the appropriate therapeutic approach.

I think it’s important to keep in mind that all of these are guidelines; they’re supposed to help the clinician make decisions, but they’re not going to replace clinical judgment. Often, the guidelines may not apply to a specific clinical scenario. The idea is to give some tools to clinicians that they can use along with their best possible judgment.

It was definitely a privilege to participate with such a great group of rheumatologists on creating the guideline for Takayasu arteritis, and a wonderful experience personally for me, as somebody who has been interested in vasculitis for many years.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michael Putman, MD (@EBRheum), is an assistant professor at the Medical College of Wisconsin, Wauwatosa, where he is the associate fellowship program director and the medical director of the vasculitis program.

References

  1. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Rheumatol. 2021 Aug; 73(8):1366–1383; and Arthritis Care Res (Hoboken). 2021 Aug; 73(8):1088–1105.
  2. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349–1365; and Arthritis Care Res (Hoboken). 2021 Aug; 73(8):1071–1087.
  3. Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol. 2021 Aug; 73(8):1384–1393; and Arthritis Care Res (Hoboken). 2021 Aug; 73(8):1061–1070.
  4. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013 Oct;17(5):603–606.
  5. Mekinian A, Resche-Rigon M, Comarmond C, et al. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. J Autoimmun. 2018 Jul; 91:55–60.
  6. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018 Mar; 77(3):348–354.
  7. Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford). 2018 Dec 1; 57(12):2101–2105.
  8. Aeschlimann FA, Eng SWM, Sheikh S, et al. Childhood Takayasu arteritis: Disease course and response to therapy. Arthritis Res Ther. 2017 Nov 22; 19(1):255.
  9. Zheng T, Zhu S, Ou J-F, et al. Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu’s arteritis. J Invest Surg. 2019 Apr; 32(3):220–227.
  10. Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Rheumatol. 2022 Apr; 74(4):586–596; and Arthritis Care Res (Hoboken). 2022 Apr;74(4):538–548.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Guidelines, Vasculitis Tagged With: guideline, Takayasu arteritis (TAK), Vasculitis, Vasculitis FoundationIssue: February 2022

You Might Also Like:
  • Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis
  • Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis
  • Vasculitis Guidelines in Focus, Part 1: The Guideline Project
  • Update on the Management of Takayasu Arteritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)